The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Characterization of Pseudomonas aeruginosa Isolates: Occurrence Rates, Antimicrobial Susceptibility Patterns, and Molecular Typing in the Global SENTRY Antimicrobial Surveillance Program, 1997–1999
Abstract
During 1997-1999, a total of 70,067 isolates (6631 Pseudomonas aeruginosa isolates) were analyzed in the SENTRY program by geographic region and body site of infection. The respiratory tract was the most common source of P. aeruginosa. P. aeruginosa isolation rates increased during the study interval. Europe was the only region to show a significant decline in beta-lactam and aminoglycoside susceptibility rates. There was a reduction in the rates of susceptibility of Canadian isolates to imipenem and of Latin American isolates to meropenem. A total of 218 multidrug-resistant P. aeruginosa isolates (MDR-PSA; resistant to piperacillin, ceftazidime, imipenem, and gentamicin) were observed; MDR-PSA occurrence rates (percentages of all isolates) ranged from 8.2% (Latin America) to 0.9% (Canada). No antimicrobial inhibited >50% of MDR-PSA strains. Molecular characterization of selected, generally resistant strains was performed. Isolates showing unique ribogroups were found in Europe, Latin America, and the United States, but clonal spread was documented in several medical centers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Manual of Clinical Microbiology.
(1980) · Annals of Internal Medicine · doi:10.7326/0003-4819-93-6-939_2 · Cited by 14,411
Principles and Practice of Infectious Diseases.
(1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-114-9-818_5 · Cited by 12,025
Vincent, J.-L. (1995) · JAMA · doi:10.1001/jama.1995.03530080055041 · Cited by 1,632
Nosocomial infections in medical intensive care units in the United States
Richards, M. J., Edwards, J. R., Culver, D. H., & Gaynes, R. P. (1999) · Critical Care Medicine · doi:10.1097/00003246-199905000-00020 · Cited by 1,565
Levin, A. S., Barone, A. A., Penço, J., Santos, M. V., Marinho, I. S., Arruda, E. A. G., Manrique, E. I., & Costa, S. F. (1999) · Clinical Infectious Diseases · doi:10.1086/514732 · Cited by 612
Resistance Mechanisms in Pseudomonas aeruginosa and Other Nonfermentative Gram‐Negative Bacteria
Hancock, R. E. W. (1998) · Clinical Infectious Diseases · doi:10.1086/514909 · Cited by 583
Polymyxin B Sulfate and Colistin: Old Antibiotics for Emerging Multiresistant Gram-Negative Bacteria
Evans, M. E., Feola, D. J., & Rapp, R. P. (1999) · Annals of Pharmacotherapy · doi:10.1345/aph.18426 · Cited by 544
Pfaller, M. A., Jones, R. N., Doern, G. V., Kugler, K., & Group, T. S. P. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.7.1762 · Cited by 539
Self-citationFridkin, S. K., Steward, C. D., Edwards, J. R., Pryor, E. R., McGowan, Jr., Archibald, L. K., Gaynes, R. P., & Tenover, F. C. (1999) · Clinical Infectious Diseases · doi:10.1086/520193 · Cited by 486
Aires, J. R., Köhler, T., Nikaido, H., & Plésiat, P. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.11.2624 · Cited by 391
Cited by
Church, D., Elsayed, S., Reid, O., Winston, B., & Lindsay, R. (2006) · Clinical Microbiology Reviews · doi:10.1128/cmr.19.2.403-434.2006 · Cited by 1,876
Talbot, G. H., Bradley, J., Edwards, J. E., Gilbert, D., Scheld, M., & Bartlett, J. G. (2006) · Clinical Infectious Diseases · doi:10.1086/499819 · Cited by 1,104
Combination Therapy for Treatment of Infections with Gram-Negative Bacteria
Tamma, P. D., Cosgrove, S. E., & Maragakis, L. L. (2012) · Clinical Microbiology Reviews · doi:10.1128/cmr.05041-11 · Cited by 836
Neuhauser, M. M., Weinstein, R. A., Rydman, R., Danziger, L. H., Karam, G., & Quinn, J. P. (2003) · JAMA · doi:10.1001/jama.289.7.885 · Cited by 678
Aminoglycoside Resistance in Pseudomonas aeruginosa
Poole, K. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.2.479-487.2005 · Cited by 470
Impact of multidrug-resistant Pseudomonas aeruginosa infection on patient outcomes
Hirsch, E. B., & Tam, V. H. (2010) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1586/erp.10.49 · Cited by 406
Ventilator-Associated Pneumonia
(2012) · SpringerReference · doi:10.1007/springerreference_225126 · Cited by 406
Lockhart, S. R., Abramson, M. A., Beekmann, S. E., Gallagher, G., Riedel, S., Diekema, D. J., Quinn, J. P., & Doern, G. V. (2007) · Journal of Clinical Microbiology · doi:10.1128/jcm.01284-07 · Cited by 396
Treatment and control of severe infections caused by multiresistant Pseudomonas aeruginosa
Rossolini, G. M., & Mantengoli, E. (2005) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2005.01161.x · Cited by 395
Karlowsky, J. A., Draghi, D. C., Jones, M. E., Thornsberry, C., Friedland, I. R., & Sahm, D. F. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.5.1681-1688.2003 · Cited by 351
Nathwani, D., Raman, G., Sulham, K., Gavaghan, M., & Menon, V. (2014) · Antimicrobial Resistance and Infection Control · doi:10.1186/2047-2994-3-32 · Cited by 344
Obritsch, M. D., Fish, D. N., MacLaren, R., & Jung, R. (2005) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.2005.25.10.1353 · Cited by 342
Gales, A. C., Jones, R. N., & Sader, H. S. (2006) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2005.01351.x · Cited by 302
Self-citationObritsch, M. D., Fish, D. N., MacLaren, R., & Jung, R. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.12.4606-4610.2004 · Cited by 288
Efficacy of common hospital biocides with biofilms of multi-drug resistant clinical isolates
Smith, K., & Hunter, I. S. (2008) · Journal of Medical Microbiology · doi:10.1099/jmm.0.47668-0 · Cited by 266
Castanheira, M., Toleman, M. A., Jones, R. N., Schmidt, F. J., & Walsh, T. R. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.12.4654-4661.2004 · Cited by 261
Self-citationPIER, G. (2007) · International Journal of Medical Microbiology · doi:10.1016/j.ijmm.2007.03.012 · Cited by 253
Ramphal, R. (2004) · Clinical Infectious Diseases · doi:10.1086/383048 · Cited by 252
Self-citation
Metadata
- Authors
- Gales, A. C., Jones, R. N., Turnidge, J., Rennie, R., & Ramphal, R.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2001-05-15
- Volume
- 32
- Issue
- s2
- Pages
- S146-S155
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2111374015
- Cited by
- 309
- References
- 39
- FWCI
- 10.88
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.